Table 3.

Prognostic values (Cox model) of ApoA1 and haptoglobin in CHC patients. (A) ApoA1 in CHC patients (n = 3349) and cardiovascular deaths (n = 40). (B) Hapto in CHC patients (n = 3349) and cardiovascular deaths (n = 40). (C) ApoA1 in CHC patients (n = 3349) and non‐liver cancer deaths (n = 63). (D). Hapto in CHC patients (n = 3349) and non‐liver cancer deaths (n = 63). (E) ApoA1 in CHC patients (n = 3349) and all deaths (n = 449). (F) Hapto in CHC patients (n = 3349) and all deaths (n = 449)

Variable	Exp(B)	95% CI	P‐value	R²
(A)
ApoA1neg	1.787	0.712‐4.484	0.216	0.007
A2M	0.444	0.055‐3.598	0.447	0.003
Age	1.072	1.046‐1.100	0.000	0.123
Male gender	2.413	1.157‐5.032	0.019	0.025
(B)
Hapto neg	0.287	0.093‐0.893	0.031	0.021
A2M	0.538	0.064‐4.503	0.568	0.002
Age	1.070	1.044‐1.098	0.000	0.115
Male gender	2.679	1.320‐5.439	0.006	0.034
(C)
ApoA1neg	2.572	1.243‐5.323	0.011	0.027
A2M	1.084	0.201‐5.840	0.925	0.000
Age	1.047	1.026‐1.069	0.000	0.078
Male gender	1.395	0.805‐2.419	0.236	0.006
(D)
Hapto neg	0.337	0.139‐0.816	0.016	0.024
A2M	1.321	0.240‐7.260	0.749	0.000
Age	1.045	1.024‐1.067	0.000	0.071
Male gender	1.689	0.994‐2.870	0.053	0.016
(E)
ApoA1neg	5.590	4.298‐7.271	0.000	0.215
A2M	1.766	0.937‐3.327	0.079	0.005
Age	1.053	1.045‐1.060	0.000	0.233
Male gender	1.434	1.164‐1.767	0.001	0.019
(E)
Hapto neg	2.224	1.777‐2.783	0.000	0.075
A2M	1.268	0.662‐2.431	0.474	0.001
Age	1.052	1.044‐1.060	0.000	0.223
Male gender	2.052	1.674‐2.516	0.000	0.074